Elisa A. Rozeman

12.9k citations

65 papers · 3.0k indexed · 3 hit papers · h-index 21

Oncology top 1%
Immunology top 2%
Molecular Biology top 10%
Pulmonary and Respiratory Medicine top 5%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Christian U. Blank John B.A.G. Haanen Ton N. Schumacher Hugo M. Horlings Alexander C. J. van Akkooi Ido Yofe Marlous van den Braber Hanjie Li
Topics: Cancer Immunotherapy and Biomarkers (51 papers)CAR-T cell therapy research (33 papers)Melanoma and MAPK Pathways (23 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: Netherlands Australia United States

In The Last Decade

Elisa A. Rozeman

63 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

2018 659 citations Hanjie Li, Anne M. van der Leun et al. Cell profile →
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

2017 504 citations Riccardo Mezzadra, Chong Sun et al. Nature profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Maartje W. Rohaan, Elisa A. Rozeman et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Elisa A. Rozeman

Since Specialization

Citations

This map shows the geographic impact of Elisa A. Rozeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa A. Rozeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa A. Rozeman more than expected).

Fields of papers citing papers by Elisa A. Rozeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa A. Rozeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa A. Rozeman. The network helps show where Elisa A. Rozeman may publish in the future.

Co-authorship network of co-authors of Elisa A. Rozeman

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa A. Rozeman. A scholar is included among the top collaborators of Elisa A. Rozeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa A. Rozeman. Elisa A. Rozeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells 2023 ·Cancer Immunology Research ·Esmée P. Hoefsmit,(unknown),Disha Rao,(unknown),Petros Dimitriadis,Cor Lieftink,Ben Morris,Elisa A. Rozeman,Irene L. M. Reijers,Ruben Lacroix,(unknown),Maarten A. Ligtenberg,Roderick L. Beijersbergen,Daniel S. Peeper,Christian U. Blank	10
2	1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma 2023 ·Annals of Oncology ·(unknown),Elisa A. Rozeman,Judith M. Versluis,Alexander M. Menzies,Hanna Eriksson,B. van de Wiel,Richard A. Scolyer,(unknown),Henk Mallo,Maria Gonzalez,(unknown),(unknown),Lindsay G. Grijpink-Ongering,John B.A.G. Haanen,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	1
3	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma 2023 ·Nature Reviews Clinical Oncology ·(unknown),Judith M. Versluis,Elisa A. Rozeman,Christian U. Blank	22
4	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response 2021 ·Proceedings of the National Academy of Sciences ·Anastasia Gangaev,Elisa A. Rozeman,Maartje W. Rohaan,Olga I. Isaeva,Daisy Philips,(unknown),Joost H. van den Berg,Antoni Ribas,Dirk Schadendorf,Bastian Schilling,Ton N. Schumacher,Christian U. Blank,John B.A.G. Haanen,Pia Kvistborg	21
5	Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4 2021 ·Clinical Cancer Research ·Oscar Krijgsman,Kristel Kemper,Julia Boshuizen,David W. Vredevoogd,Elisa A. Rozeman,(unknown),Beaunelle de Bruijn,Paulien Cornelissen‐Steijger,Aida Shahrabi,Martin Del Castillo Velasco‐Herrera,Ji‐Ying Song,Maarten A. Ligtenberg,(unknown),Thomas Kuilman,Petra Ross‐Macdonald,John B.A.G. Haanen,David J. Adams,Christian U. Blank,Daniel S. Peeper	3
6	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma 2021 ·European Journal of Cancer ·Judith M. Versluis,Irene L. M. Reijers,Elisa A. Rozeman,Alexander M. Menzies,Alexander C. J. van Akkooi,Michel W.J.M. Wouters,Sydney Ch’ng,Robyn P.M. Saw,Richard A. Scolyer,Bart A. van de Wiel,Bastian Schilling,Georgina V. Long,Christian U. Blank	14
7	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance 2020 ·Nature Communications ·Julia Boshuizen,David W. Vredevoogd,Oscar Krijgsman,Maarten A. Ligtenberg,(unknown),Beaunelle de Bruijn,Dennie T. Frederick,Juliana C.N. Kenski,Mara Parren,(unknown),Max F. Madu,Elisa A. Rozeman,Ji‐Ying Song,Hugo M. Horlings,Christian U. Blank,Alexander C. J. van Akkooi,Keith T. Flaherty,Genevieve M. Boland,Daniel S. Peeper	66
8	Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma 2019 ·Pigment Cell & Melanoma Research ·Irene L. M. Reijers,Elisa A. Rozeman,Sofie Wilgenhof,Johannes V. van Thienen,John B.A.G. Haanen,Christian U. Blank	9
9	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events 2019 ·ESMO Open ·Esmée P. Hoefsmit,Elisa A. Rozeman,John B.A.G. Haanen,Christian U. Blank	28
10	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). 2019 ·Journal of Clinical Oncology ·Alexander M. Menzies,Elisa A. Rozeman,Rodabe Navroze Amaria,Alexander C. Huang,Richard A. Scolyer,Michael T. Tetzlaff,Bart A. van de Wiel,Serigne Lo,Ahmad A. Tarhini,Hussein Tawbi,Elizabeth M. Burton,Giorgos C. Karakousis,Paolo A. Ascierto,Andrew J. Spillane,Michael A. Davies,Alexander Christopher Jonathan Van Akkooi,Tara C. Mitchell,Georgina V. Long,Jennifer A. Wargo,Christian U. Blank	63
11	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors 2018 ·Cancer Immunology Research ·Emma C. de Moel,Elisa A. Rozeman,Ellen Kapiteijn,Els M.E. Verdegaal,Annette Grummels,Jaap Bakker,T. Huizinga,John B.A.G. Haanen,René E. M. Toes,Diane van der Woude	129
12	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management 2018 ·ESMO Open ·Marnix H. Geukes Foppen,Elisa A. Rozeman,Sandra van Wilpe,Cindy Postma,Pétur Snæbjörnsson,Johannes V. van Thienen,Monique E. van Leerdam,Michel M. van den Heuvel,Christian U. Blank,Jolanda van Dieren,John B.A.G. Haanen	199
13	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) 2018 ·Annals of Oncology ·Christian U. Blank,Elisa A. Rozeman,Alexander M. Menzies,Bart A. van de Wiel,Chandra Mani Adhikari,Karolina Sikorska,Oscar Krijgsman,Hanna Eriksson,Carolien Bierman,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Annegien Broeks,Alexander Guminski,Andrew J. Spillane,W. Martin C. Klop,Robyn P.M. Saw,Richard A. Scolyer,Alexander C. J. van Akkooi,Johan Hansson,Georgina V. Long	12
14	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanomabreakdown → 2018 ·Cell ·Hanjie Li,Anne M. van der Leun,Ido Yofe,Yaniv Lubling,(unknown),Alexander C. J. van Akkooi,Marlous van den Braber,Elisa A. Rozeman,John B.A.G. Haanen,Christian U. Blank,Hugo M. Horlings,Eyal David,Yael Baran,Akhiad Bercovich,Aviezer Lifshitz,Ton N. Schumacher,Amos Tanay,Ido Amit	659
15	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives 2017 ·American Journal of Clinical Dermatology ·Elisa A. Rozeman,Tim Dekker,John B.A.G. Haanen,Christian U. Blank	78
16	(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses 2017 ·Annals of Oncology ·Elisa A. Rozeman,Lorenzo F. Fanchi,Alexander C. J. van Akkooi,Pia Kvistborg,(unknown),(unknown),Brian D. Lamon,J.B.A.G. Haanen,Ton N. Schumacher,Christian U. Blank	10
17	Identification of CMTM6 and CMTM4 as PD-L1 protein regulatorsbreakdown → 2017 ·Nature ·Riccardo Mezzadra,Chong Sun,Lucas T. Jae,Raquel Gomez-Eerland,Evert de Vries,Wei Wu,Meike E. W. Logtenberg,Maarten Slagter,Elisa A. Rozeman,Ingrid Hofland,Annegien Broeks,Hugo M. Horlings,Lodewyk F.A. Wessels,Christian U. Blank,Yanling Xiao,Albert J. R. Heck,Jannie Borst,Thijn R. Brummelkamp,Ton N. Schumacher	504
18	Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) 2017 ·Annals of Oncology ·Elisa A. Rozeman,(unknown),Jules Gadiot,Marnix H. Geukes Foppen,Loes M. Pronk,Johannes V. van Thienen,John B.A.G. Haanen,(unknown)	3
19	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO) 2016 ·Annals of Oncology ·Yanina Jansen,Elisa A. Rozeman,(unknown),Marnix Geukes Foppen,Max Schreuer,Johannes V. van Thienen,Lars Bastholt,Henrik Schmidt,John B.A.G. Haanen,Inge Marie Svane,Ana Arance,Christian U. Blank,Bart Neyns	4
20	(Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial 2016 ·Annals of Oncology ·(unknown),Alexander C. J. van Akkooi,Elisa A. Rozeman,Pia Kvistborg,(unknown),(unknown),Brian D. Lamon,John B.A.G. Haanen,Ton N. Schumacher	9

About Elisa A. Rozeman

Elisa A. Rozeman is a scholar working on Oncology, Immunology and Molecular Biology, having authored 65 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (51 papers), CAR-T cell therapy research (33 papers) and Melanoma and MAPK Pathways (23 papers). The work is most often cited by research in Oncology (2.1k citations), Immunology (1.3k citations) and Cancer Research (278 citations). Elisa A. Rozeman has collaborated with scholars based in Netherlands, Australia and United States. Frequent co-authors include Christian U. Blank, John B.A.G. Haanen, Ton N. Schumacher, Hugo M. Horlings, Alexander C. J. van Akkooi, Ido Yofe, Marlous van den Braber, Hanjie Li, Akhiad Bercovich and Yael Baran. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact